StockGuide AI
Track Stocks
EN RU ES
Avadel Pharmaceuticals

Avadel Pharmaceuticals

Price: 21.64

Company and Business Model

Avadel Pharmaceuticals is a healthcare company focused on developing and commercializing innovative therapies for patients with rare diseases and central nervous system disorders. Its core products include the sodium oxybate formulation, which targets narcolepsy, and other specialty pharmaceuticals. The company primarily generates revenue through product sales and licensing agreements.

Investment Profile

The investment profile of Avadel Pharmaceuticals is more aligned with growth investors, given its focus on innovative therapies and potential for revenue expansion. The stock may appeal to those seeking long-term capital appreciation rather than immediate income, as it does not currently offer dividends.

Official website

Fundamental metrics (experimental)

EPS (TTM) — earnings per share for the last 12 months, $
0.00 OK
Revenue QoQ — quarter-over-quarter revenue growth
13.7% ↑
EPS surprise
-162.5% worse than expected
20d volatility
0.2% stable
FMP / FinFeed data updated: 2026-06-06
Reco: Hold Potential: 51 Risk: 69 Updated: 2026-06-11 05:30
How recommendation works
Why AI thinks so:
Weak fundamentals and high risk limit upside potential.

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell
AI recommendation changes
Date Before After Reason
2026-05-08 15:06 — Hold Weak fundamentals and high risk offset potential upside.
2026-05-08 05:19 Hold Hold Компания показывает положительную динамику роста за последние 60 и 120 дней, однако низкий EPS и отрицательный сюрприз по доходам указывают на определенные риски.
2026-03-27 07:56 Buy Hold Компания показывает рост за последние 60 и 120 дней, однако низкий EPS и высокая степень неожиданности в отчетах указывают на потенциальные риски.
Analyst forecasts
Date Analyst Action Target Price Then
2025-11-20 11:38 Wells Fargo Target Raised 20 → 22.5 23.015
2025-10-28 07:48 UBS Update — → 20 18.56
2025-10-23 11:37 H.C. Wainwright Rating Downgraded — → 20 18.525